L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review

Simutis I.S.; Semigolovskii N.Yu.; Lobachenko I.G.; Sapegin A.A.; Danilov M.S.; Iusupov E.S.; Enkina T.N.; Blitsyn K.; Karpov I.E.; Suvorova I.V.

doi:https://doi.org/10.17116/kardio20261902175

Simutis I.S.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia;
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia

SPIN RSCI: 3619-2048
ORCID: 0000-0002-2537-0142

Semigolovskii N.Yu.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia;
Sankt-Petersburg State University, St. Petersburg, Russia

ORCID: 0000-0003-4168-1853

Lobachenko I.G.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

SPIN RSCI: 5580-0699
ORCID: 0009-0007-5787-9115

Sapegin A.A.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

SPIN RSCI: 7811-3067
ORCID: 0000-0002-6433-2659

Danilov M.S.

SPIN RSCI: 4663-4987
ORCID: 0000-0001-5961-7433

Iusupov E.S.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

ORCID: 0000-0002-4716-0314

Enkina T.N.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia;
Medical Academy named after F.I. Inozemtsev, St. Petersburg, Russia

Blitsyn K.

North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia

ORCID: 0000-0002-2347-0123

Karpov I.E.

North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia

ORCID: 0009-0000-6520-9399

Suvorova I.V.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia;
Almazov National Medical Research Center, St. Petersburg, Russia

ORCID: 0000-0003-0183-8166

L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review

Authors:

Simutis I.S., Semigolovskii N.Yu., Lobachenko I.G., Sapegin A.A., Danilov M.S., Iusupov E.S., Enkina T.N., Blitsyn K., Karpov I.E., Suvorova I.V.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2026;19(2): 75‑85

DOI: 10.17116/kardio20261902175

Read: 371 times

Contact the author

Table of contents

To cite this article:

Simutis IS, Semigolovskii NYu, Lobachenko IG, et al. L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review. Russian Journal of Cardiology and Cardiovascular Surgery. 2026;19(2):75‑85. (In Russ.)
https://doi.org/10.17116/kardio20261902175

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

RELEVANCE

Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide. In recent years, significant attention has been given to L-arginine, a conditionally essential amino acid that serves as a key precursor of nitric oxide, a critically important mediator of vascular function. Dysregulation of L-arginine metabolism and the development of endothelial dysfunction play a significant pathogenetic role in the development and progression of CVDs.

OBJECTIVE

This review aims to systematize current data on the role of L-arginine in the regulation of vascular tone, its impact on endothelium-dependent vasodilation, and to assess the potential application of L-arginine in the intensive care of cardiovascular diseases.

MATERIAL AND METHODS

A comprehensive analysis of the results of in vitro and in vivo experimental studies, as well as clinical trials focused on examining the influence of L-arginine on endothelial function, hemodynamic parameters, coronary blood flow, and other cardiovascular system parameters was conducted. Particular attention was given to analyzing the molecular mechanisms of NO-mediated action of L-arginine and its interaction with the arginase enzyme.

RESULTS

L-arginine contributes to enhancing endothelium-dependent vasodilation, reducing blood pressure, and can have a positive impact in cases of coronary heart disease, heart failure, and atherosclerosis. It is important to note that the effectiveness of L-arginine therapy can be modulated by the level of ADMA, an endogenous inhibitor of nitric oxide synthase (NOS).

CONCLUSION

L-arginine represents a promising therapeutic agent for use in the intensive care of CVDs, especially in patients facing potential ischemia-reperfusion syndrome. To determine optimal therapeutic strategies, including dosage selection and identification of target patient groups, further large-scale, placebo-controlled clinical studies are necessary.

Keywords:

L-arginine

nitric oxide

endothelial dysfunction

cardiovascular diseases

arginase

asymmetric dimethylarginine (ADMA)

Authors:

Simutis I.S.

SPIN RSCI: 3619-2048
ORCID: 0000-0002-2537-0142

Semigolovskii N.Yu.

ORCID: 0000-0003-4168-1853

Lobachenko I.G.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

SPIN RSCI: 5580-0699
ORCID: 0009-0007-5787-9115

Sapegin A.A.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

SPIN RSCI: 7811-3067
ORCID: 0000-0002-6433-2659

Danilov M.S.

SPIN RSCI: 4663-4987
ORCID: 0000-0001-5961-7433

Iusupov E.S.

North-Western District Scientific and Clinical Center Named after L. G. Sokolov of the Federal Medical and Biological Agency, St. Petersburg, Russia

ORCID: 0000-0002-4716-0314

Enkina T.N.

Blitsyn K.

North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia

ORCID: 0000-0002-2347-0123

Karpov I.E.

North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia

ORCID: 0009-0000-6520-9399

Suvorova I.V.

ORCID: 0000-0003-0183-8166

Received:

10.01.2026

Accepted:

30.01.2026

Close metadata

References:

Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease: dream or reality? Vasc Med. 2002;7(3):203-211. https://doi.org/10.1191/1358863×02vm434ra
Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004;134:2842S-2847S. https://doi.org/10.1093/jn/134.10.2842S.discussion2853S.
Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20(Suppl 12):S60-S62.
Chatterjee A, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol. 2008;49(4-6): 134-140.
Gambardella J, Khondkar W, Morelli MB, Wang X, Santulli G, Trimarco V. Arginine and Endothelial Function. Biomedicines. 2020;8(8):277. https://doi.org/10.3390/biomedicines8080277
Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease: dream or reality? Vasc Med. 2002;7(3):203-211. https://doi.org/10.1191/1358863×02vm434ra
Golovchenko YuI, Treshchinskaya MA. Review of modern concepts of endothelial dysfunction. Consilium Medicum Ukraina. 2008;(11):38-40. (In Russ.).
Cziráki A, Lenkey Z, Sulyok E, Szokodi I, Koller A. L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation: Translation of Basic Science Results to Clinical Practice. Front Pharmacol. 2020;11:569914. https://doi.org/10.3389/fphar.2020.569914
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288(5789):373-376. https://doi.org/10.1038/288373a0
Shabeeh H, Melikian N, Dworakowski R, Casadei B, Chowienczyk P, Shah AM. Differential role of endothelial versus neuronal nitric oxide synthase in the regulation of coronary blood flow during pacing-induced increases in cardiac workload. Am J Physiol. Heart Circ. Physiol. 2013;304(9):H1277-H1282. https://doi.org/10.1152/ajpheart.00927.2012
Markov KhM. L-arginine — nitric oxide in the treatment of cardiovascular diseases. Cardiology. 2005;6:87-95. (In Russ.).
Sosunov AA. Nitric oxide as an intercellular mediator. Soros Educational Journal. 2000;6(12):27-34. (In Russ.).
Di Luozzo G, Bhargava J, Powell RJ. Vascular smooth muscle cell effect on endothelial cell endothelin-1 production. J Vasc Surg. 2000;31(4):781-789. https://doi.org/10.1067/mva.2000.103788
Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: Reversal of arginine steal? Cardiovasc Res. 2013;98:334-343.
Pandey D, Romer L, Berkowitz DE. Arginase II: Atherogenesis beyond enzyme activity. J Am Heart Assoc. 2013;2:e000392.
Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol. 1996;114(1):107-132. https://doi.org/10.1016/0305-0491(95)02138-8.
Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol. 2004;37(2):515-523. https://doi.org/10.1016/j.yjmcc.2004.05.004
Romero MJ, Platt DH. Tawfik HE. Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res. 2008;102:95-102.
Hein TW, Zhang C, Wang W, Chang C-I, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003;17(15):2328-2330. https://doi.org/10.1096/fj.03-0115fje
Li H, Meininger CJ, Hawker JR, Haynes, TE, Kepka-Lenhart D, Mistry SK, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280(1):E75-E82. https://doi.org/10.1152/ajpendo.2001.280.1.E75
Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M, Jung C, Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 2012;126:2943-2950.
Kovamees O, Shemyakin A, Pernow J. Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PloS One. 2014;9(7): e103260. https://doi.org/10.1371/journal.pone.0103260
Teupser D, Burkhardt R, Wilfert W, Haffner I, Nebendahl K, Thiery J. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol. 2006;26:365-371.
Katusic ZS. Mechanisms of endothelial dysfunction induced by aging: Role of arginase I. Circ Res. 2007;101:640-641.
Sun D, Messina EJ, Koller A, Wolin, MS, Kaley G. Endothelium-dependent dilation to L-arginine in isolated rat skeletal muscle arterioles. Am J Physiol. 1992;262(4 Pt 2):H1211-H1216. https://doi.org/10.1152/ajpheart.1992.262.4.H1211.
Cherry PD, Furchgott, RF, Zawadzki JV, Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci U S A. 1982;79(6):2106-2110. https://doi.org/10.1073/pnas.79.6.2106
Padro T, Manfrini O, Bugiardini R, Canty J, Cenko E, De Luca G, et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease’. Cardiovasc Res. 2020;116(4):741-755. https://doi.org/10.1093/cvr/cvaa003
Tousoulis D, Boger RH, Antoniades C, Siasos G, Stefanadi E, Stefanadis C. Mechanisms of disease: L-arginine in coronary atherosclerosis — a clinical perspective. Nat Clin Pract Cardiovasc Med. 2007;4(5):274-283. https://doi.org/10.1038/ncpcardio0878
Berkowitz DE, White R, Li, D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC. ea. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000-2006.
Quyyumi AA. Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and L-arginine. J Am Coll. Cardiol. 1998;32(4):904-911. https://doi.org/10.1016/s0735-1097(98)00323-4
Udvardy M, Posan E, Palatka, K, Altorjay I, Harsfalvi J. Effect of L-arginine on in vitro plasmin-generation and fibrinogenolysis. Thromb Res. 1997;87(1):75-82. https://doi.org/10.1016/s0049-3848(97)00106-0
Walter R, Mark M, Reinhart WH. Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. Biochem Biophys Res Commun. 2000;269(3):687-691. https://doi.org/10.1006/bbrc.2000.2344
Kurhaluk N, Lukash O, Kamiński P, Tkaczenko H. L-Arginine and Intermittent Hypoxia Are Stress-Limiting Factors in Male Wistar Rat Models. International Journal of Molecular Sciences. 2024;25(22):12364. https://doi.org/10.3390/ijms252212364
Dong JY, Qin LQ, Zhang Z, Zhao Y, Wang J, Arigoni F, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011;162(6):959-965. https://doi.org/10.1016/j.ahj.2011.09.012
Hishikawa K, Nakaki T, Tsuda M, Esumi H, Ohshima H, Suzuki H, et al. Effect of systemic L-arginine administration on hemodynamics and nitric oxide release in man. Jpn Heart J. 1992;33(1), 41-48. https://doi.org/10.1536/ihj.33.41
Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, et al. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab. 1995;80(7):2198-2202. https://doi.org/10.1210/jcem.80.7.7608279
Neri I, Monari F, Sgarbi L, Berardi A, Masellis G, Facchinetti F. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern Fetal Neonatal Med. 2010;23(12):1456-1460. https://doi.org/10.3109/14767051003677962
Chen S-F, Pan M-X, Tang J-C, et al. Arginine is neuroprotective through suppressing HIF-1α/LDHA-mediated inflammatory response after cerebral ischemia/reperfusion injury. Mol Brain 2020;13:63. https://doi.org/10.1186/s13041-020-00601-9
Ku DD. Coronary vascular reactivity after acute myocardial ischemia. Science 1982;218(4572):576-578. https://doi.org/10.1126/science.7123259
Ajtay Z, Nemeth A, Sulyok E, Cziraki A, Szabados S, Martens-Lobenhoffer J, et al. Effects of stent implementation on plasma levels of asymmetric dimethylarginine in patients with or without ST-segment elevation acute myocardial infarction. Int J Mol Med. 2010;25(4):617-624. https://doi.org/10.3892/ijmm_00000384
Padilla F, Garcia-Dorado D, Agullo L, Inserte J, Paniagua A, Mirabet S, Barrabes JA, Ruiz-Meana M, Soler-Soler J. L-Arginine administration prevents reperfusion-induced cardiomyocyte hypercontracture and reduces infarct size in the pig. Cardiovasc Res. 2000;46:412-420.
Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261-269.
Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295(1):58-64. https://doi.org/10.1001/jama.295.1.58
Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80(3):331-333. https://doi.org/10.1016/s0002-9149(97)00354-8
Walker HA, McGing E, Fisher I, Boger RH, Bode-Boger SM, Jackson G, Ritter JM, Chowienczyk PJ. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: Lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol. 2001;38:499-505.
Tousoulis D, Tentolouris C, Crake T, Katsimaglis G, Stefanadis C, Toutouzas P, et al. Effects of L- and D-arginine on the basal tone of human diseased coronary arteries and their responses to substance P. Heart 1999;81(5):505-511. https://doi.org/10.1136/hrt.81.5.505
Dubois-Rande JL, Zelinsky R, Roudot F, Chabrier PE, Castaigne A, Geschwind H, et al. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol. 1992;70(15):1269-1275. https://doi.org/10.1016/0002-9149(92)90760-v
Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94(2):130-134. https://doi.org/10.1161/01.cir.94.2.130
Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO 3rd. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997;30(5):1220-1227. https://doi.org/10.1016/s0735-1097(97)00279-9
Lerman A, Burnett JCJr, Higano ST, McKinley LJ, Holmes DRJr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123-2128. https://doi.org/10.1161/01.cir.97.21.2123.
Yin W-H, Chen J-W, Tsai C, Chiang M-C, Young MS, Lin S-J. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr. 2005 Dec;24(6):988-997.
Bosmans JM, Vrints CJ, Kockx MM, Bult H, Cromheeke KM, Herman AG. Continuous perivascular L-arginine delivery increases total vessel area and reduces neointimal thickening after experimental balloon dilatation. Arterioscler Thromb Vasc Biol. 1999;19(3):767-776. https://doi.org/10.1161/01.atv.19.3.76
Shiraki T, Takamura T, Kajiyama A, Oka T, Saito D. Effect of short-term administration of high dose L-arginine on restenosis after percutaneous transluminal coronary angioplasty. J Cardiol. 2004;44(1):13-20. PMID: 15334880.
Suzuki T, Hayase M, Hibi K, Hosokawa H, Yokoya K, Fitzgerald PJ, et al. Effect of local delivery of L-arginine on in-stent restenosis in humans. Am J Cardiol. 2002;89(4):363-367. https://doi.org/10.1016/s0002-9149(01)02252-4
Mohammadi Z, Ravankhah M, Ahmadi M, Keshavarzian O, Azari I, Abdollahi M, Rezaei M, Akbari H. L-arginine impact on inflammatory and cardiac markers in patients undergoing coronary artery bypass graft: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2024;24(1):641. https://doi.org/10.1186/s12872-024-04318-8
Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J, Geny B. Chronic L-arginine supplementation enhances endurance exercise tolerance in heart failure patients. Int J Sports Med. 2006;27:567-572.
Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol. 1996;27:1207-1213.
Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: No benefit and possible harm. Circulation. 2007;116:188-195.
Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO, III. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women. J Am Coll Cardiol. 2000;35:271-276.
Deveaux A, Fouillet H, Petzke KJ, Hermier D, Andre E, Bunouf P, Lantoine-Adam F, Benamouzig R, Mathe V, Huneau JF, et al. A Slow-Compared with a Fast-Release Form of Oral Arginine Increases Its Utilization for Nitric Oxide Synthesis in Overweight Adults with Cardiometabolic Risk Factors in a Randomized Controlled Study. J Nutr. 2016;146:1322-1329.
Kuramochi Y, Murata M, Sumino A, Sone H, Hayamizu K. Safety assessment of L-Arg oral intake in healthy subjects: a systematic review of randomized control trials. Amino Acids. 2023 Dec; 55(12):1949-1964. https://doi.org/10.1007/s00726-023-03354-6
Cynober L, Bier DM, Kadowaki M, Morris SMJr, Elango R, Smriga M. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly. J Nutr. 2016;146(12):2652S-2654S. https://doi.org/10.3945/jn.115.228478.
Schneider JY, Rothmann S, Schroder F, Langen J, Lucke T, Mariotti F, et al. Effects of chronic oral L-arginine administration on the L-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: L-Arginine prevents renal loss of nitrite, the major NO reservoir. Amino Acids. 2015;47(9):1961-1974. https://doi.org/10.1007/s00726-015-2031-0
Morita M, Hayashi T, Ochiai M, Maeda M, Yamaguchi T, Ina K, et al. Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochem Biophys Res Commun. 2014;454(1):53-57. https://doi.org/10.1016/j.bbrc.2014
Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005;10(Suppl 1):S19-S25. https://doi.org/10.1177/1358836X0501000104.
Dioguardi FS. To give or not to give? Lessons from the arginine paradox. J Nutrigenet Nutrige. 2011;4:90-98.
Bartnicki P, Kowalczyk M, Franczyk-Skora B, Baj Z, Rysz J. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. Curr Vasc Pharmacol. 2016;14:360-367.
Janes F, Cifu A, Pessa ME, Domenis R, Gigli GL, Sanvilli N, Nilo A, Garbo R, Curcio F, Giacomello R, et al. ADMA as a possible marker of endothelial damage. A study in young asymptomatic patients with cerebral small vessel disease. Sci Rep. 2019;9:14207.
Wijnands KA, Hoeksema MA, Meesters DM, van den Akker NM, Molin DG, Briede JJ, Ghosh M, Kohler SE, van Zandvoort MA, de Winther MP, et al. Arginase-1 deficiency regulates arginine concentrations and NOS2-mediated NO production during endotoxemia. PLoS One. 2014;9:e86135
Chirinos JA, David R, Bralley JA, Zea-Diaz H, Munoz-Atahualpa E, Corrales-Medina F, Cuba-Bustinza C, Chirinos-Pacheco J, Medina-Lezama J. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: The Prevencion Study. Hypertension. 2008;52.
Abedini S, Meinitzer A, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A, Holdaas H. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010;77:44-50.
Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM,van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 2005;68:2230-2236.
Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y. Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: An epidemiological study. Atherosclerosis. 2007;191:206-210.
Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, Benndorf R, Schulze F, Vasan RS, Wolf PA, Böger RH, Seshadri S. Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke. 2009;40:2715-2719.
Bai Y, Sun L, Du L, Zhang T, Xin W, Lan X, Du G. Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: Evidence from 6168 participants. Ageing Res Rev. 2013;12:699-707.
Mangiacapra F, Conte M, Demartini C, Muller O, Delrue L, Dierickx K, et al. Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. Int J Cardiol. 2016;220:629-633. https://doi.org/10.1016/j.ijcard.2016.06.254
Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833. https://doi.org/10.1161/JAHA.115.001833
Tousoulis D, Georgakis MK, Oikonomou E, Papageorgiou N, Zaromitidou M, Latsios G, et al. Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches. Curr Med Chem. 2015;22(24):2871-2901. https://doi.org/10.2174/0929867322666150625095046
Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol. 2003;26(10):458-464. https://doi.org/10.1002/clc.4960261006
Kruszelnicka O, Surdacki A, Golay A. Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study. Cardiovasc. Diabetol. 2013;12:145. https://doi.org/10.1186/1475-2840-12-145
Schulze, F, Lenzen, H, Hanefeld, C, Bartling, A, Osterziel, KJ, Goudeva, L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1-493.e8. https://doi.org/10.1016/j.ahj.2006.06.005
Veresh Z, Debreczeni B, Hamar J, Kaminski PM, Wolin MS, Koller A. Asymmetric dimethylarginine reduces nitric oxide donor-mediated dilation of arterioles by activating the vascular renin-angiotensin system and reactive oxygen species. J Vasc Res. 2012;49(4):363-372. https://doi.org/10.1159/000337485
Parikh RV, Khush KK, Luikart H, Pargaonkar VS, Kobayashi Y, Lee JH, et al. Impact of Asymmetric Dimethylarginine on Coronary Physiology Early After Heart Transplantation. Am J Cardiol. 2017;120(6):1020-1025. https://doi.org/10.1016/j.amjcard.2017.06.036
Ajtay Z, Scalera F, Cziraki A, Horvath I, Papp L, Sulyok E, et al. Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA. Int J Mol Med. 2009;23(5):651-657. https://doi.org/10.3892/ijmm_00000176
Notsu Y, Yano S, Shibata H, Nagai A, Nabika T. Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. Atherosclerosis. 2015;239:61-66.
Boger RH, Endres HG, Schwedhelm E, Darius H, Atzler D, Luneburg N, von Stritzky B, Maas R, Thiem U, Benndorf RA, et al. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J Intern Med. 2011;269:349-361.
Pizzarelli F, Maas R, Dattolo P, Tripepi G, Michelassi S, D’Arrigo G, Mieth M, Bandinelli S, Ferrucci L, Zoccali C. Asymmetric dimethylarginine predicts survival in the elderly. Age. 2013;35: 2465-2475.